New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:03 EDTBDSIBioDelivery Sciences completes enrollment for Phase 3 trial of Clonidine
BioDelivery Sciences has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the FDA. FDA has granted Fast Track designation for the program.
News For BDSI From The Last 14 Days
Check below for free stories on BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
August 12, 2014
07:11 EDTBDSIBioDelivery Sciences and Endo Pharmaceuticals report on BEMA Buprenorphine NDA
Subscribe for More Information
August 8, 2014
09:00 EDTBDSIBioDelivery Sciences still a takeover target, says Janney Capital
Janney Capital continues to believe that BioDelivery Sciences (BDSI) could be a takeover target, noting that it thinks partner Endo International (ENDP) could be a potential buyer if BioDelivery has more positive top-line results and if the market weakens. The firm, which added that it likes BioDelivery Sciences as a stand-alone company as well, maintains its Buy rating and $15 fair value estimate on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use